Skip to main content Skip to main navigation menu Skip to site footer

High-risk human papillomavirus prevalence among patients with cervical cancer at Moewardi General Hospital in Surakarta, Indonesia

  • Brian Wasita ,
  • Suyatmi ,
  • Riza Novierta Pesik ,
  • Ratih Dewi Yudhani ,
  • Nanang Wiyono ,
  • Rachmi Fauziah Rahayu ,
  • Kristanto Yuli Yarso ,
  • pdf  |
  • Published: 2023-06-19


Link of Video Abstract:


Introduction: In Indonesia, cervical cancer is the second most prevalent type of cancer among the general population. Cervical cancer has the second-highest mortality rate of all cancers. Infection with the Human Papilloma Virus (HPV) is one of the causes that starts the growing phase of cervical cancer. The purpose of this study, therefore, is to determine the prevalence of HPV infection in patients with cervical cancer who were examined at Dr. Moewardi Hospital and lived in the ex-Surakarta Residency.

Methods: Cervical tissue biopsy at the Anatomical Pathology Installation of Dr. Moewardi General Hospital Surakarta which had been diagnosed as cervical cancer was examined by the detection of E6 protein from HPV 16 and HPV 18 using immunohistochemical staining techniques. The data obtained would be analyzed based on the characteristics of the patient's age and the degree of histopathological malignancy with a p-value < 0.05 deemed significant.

Results: Overall, the prevalence of high-risk HPV infection was 77.8% (35/45), with women aged between 41-55 years having the highest prevalence of HPV infection (45.7, 16/35), followed by women aged 56-70 (42.9%), women over 70 (8.6%) and women under 40 (2.9%). The results of statistical tests showed that no significant relationship was found between HPV infection and age (p = 0.428). High-risk HPV infection was most prevalent in the poorly differentiated group (54.3%), followed by the well-differentiated group (34.3%) and the moderately differentiated group (11.4%). The results of statistical tests revealed a significant association between HPV infection and tumor grade (p = 0.027).

Conclusion: To lower patient morbidity and mortality, it is crucial to receive a prophylactic HPV vaccine due to the incidence of HPV 16 and 18 infections in patients with cervical cancer at the Regional Hospital Dr. Moewardi Surakarta, with a prevalence of 77.8%.


  1. Nuranna L, Aziz MF, Cornain S, Purwoto G, Purbadi S, Budiningsih S, et al. Cervical cancer prevention program in Jakarta, Indonesia: See and Treat model in developing country. J Gynecol Oncol. 2012/07/02. 2012;23(3):147–52. Available from:
  2. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. Human Papillomavirus and Related Diseases in the World [Internet]. 2019. Available from:
  3. Domingo EJ, Noviani R, Noor MRM, Ngelangel CA, Limpaphayom KK, Van Thuan T, et al. Epidemiology and Prevention of Cervical Cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine. 2008;26:M71–9. Available from:
  4. GLOBOCAN. Global Cancer Report: Indonesia. 2020.
  5. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018;144(8):1941–53. Available from:
  6. Escobar N, Plugge E. Prevalence of human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer in imprisoned women worldwide: a systematic review and meta-analysis. J Epidemiol Community Health (1978). 2019;74(1):95–102. Available from:
  7. Prasetyo RE, Mastutik G, Mustokoweni S. Prevalence of Human Papillomavirus Genotypes in Low and High-Grade Squamous Intraepithelial Lesions at Cervical Tissue. Folia Medica Indonesiana. 2017;53(4):258. Available from:
  8. Awua AK, Sackey ST, Osei YD, Asmah RH, Wiredu EK. Prevalence of human papillomavirus genotypes among women with cervical cancer in Ghana. Infect Agent Cancer. 2016;11:4. Available from:
  9. Lagheden C, Eklund C, Lamin H, Kleppe SN, Lei J, Elfström KM, et al. Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. Br J Cancer. 2018/03/21. 2018;118(10):1377–81. Available from:
  10. Mahendra Dewi I G.A.S. The risk of cervical adenocarcinoma in patients infected with human papillomavirus type-18 is three times higher than in other high-risk types. Bali Medical Journal. 2017;2(3):S29–32. Available from:
  11. Mastutik G, Rahniayu A, Kurniasari N, Rahaju AS, Harjanto B. Distribution of Human Papilloma Virus (HPV) in Cervical Adenocarcinoma and Adenosquamous Carcinoma. Folia Medica Indonesiana. 2021;57(2):170. Available from:
  12. Savira M, Suhaimi D, Putra AE, Yusrawati Y, Lipoeto NI. Prevalence Oncogenic Human Papillomavirus in Cervical Cancer Patients in Riau Province Indonesia. Rep Biochem Mol Biol. 2022;10(4):573–9. Available from:
  13. Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: A molecular driver in cervical cancer pathogenesis. Cancer Lett. 2020/10/07. 2021;496:104–16. Available from:
  14. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. Available from:
  15. Dewi IGASM, Sriwidyani NP, Ekawati NP. The role of epidermal growth factor receptor as progression factor in cervical intraepithelial neoplasia and squamous cell carcinoma. Bali Medical Journal. 2021;10(1):238–42.
  16. Tobing MDL, Sahiratmadja E, Dinda M, Hernowo BS, Susanto H. Human Papillomavirus Genotypes Profile in Cervical Cancer Patients at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Asian Pacific Journal of Cancer Prevention. 2014;15(14):5781–5. Available from:
  17. Schellekens MC, Dijkman A, Aziz MF, Siregar B, Cornain S, Kolkman-Uljee S, et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol. 2004;93(1):49–53. Available from:
  18. Vet JNI, de Boer MA, van den Akker BEWM, Siregar B, Lisnawati, Budiningsih S, et al. Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. Br J Cancer. 2008;99(1):214–8. Available from:
  19. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553–60. Available from:
  20. Agus Somia IK, Merati TP, Sukmawati DD, Agung Elis Indira IGA, Putra Dwija IBN, Oktavian Prasetia MY, et al. Prevalence of and risk factors associated with anal HPV infection among men who have sex with men in Bali, Indonesia. Bali Medical Journal. 2020;9(3):646–53.
  21. Farag EBA, Elhasan LE, Bansal D, Osman O, Enan K. Prevalence of human papillomavirus type 16 in Sudanese women diagnosed with cervical carcinoma. J Cancer Res Ther. 2019;15(6):1316. Available from:
  22. Setiawan D, Andrijono, Hadinegoro SR, Meyta H, Sitohang RV, Tandy G, et al. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis. PLoS One. 2020;15(3):e0230359–e0230359. Available from:

How to Cite

Brian Wasita, Suyatmi, Riza Novierta Pesik, Ratih Dewi Yudhani, Nanang Wiyono, Rachmi Fauziah Rahayu, & Kristanto Yuli Yarso. (2023). High-risk human papillomavirus prevalence among patients with cervical cancer at Moewardi General Hospital in Surakarta, Indonesia. Bali Medical Journal, 12(2), 1918–1921. Retrieved from




Search Panel